mProX™ Human MLNR Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- GPCR Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human MLNR Stable Cell Line (S01YF-0923-PY123). Click the button above to contact us or submit your feedback about this product.
William (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Jessica (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The DNA damage-up phenotypes were validated by MLNR knockdown using two separate siRNAs.
Knockdown experiments using two distinct siRNAs, targeting MLNR, MME, and POMC, successfully validated the induction of DNA damage-associated traits. The assessment of DNA damage was performed through either the median fluorescence intensity measurement or the identification of a DNA-damage positive subpopulation. Displayed below are representative dot plots from flow cytometry illustrating instances of the DNA-damage positive subpopulation.
Ref: Liu, Yanhong, et al. "Rare deleterious germline variants and risk of lung cancer." NPJ precision oncology 5.1 (2021): 12.
Pubmed: 33594163
DOI: 10.1038/s41698-021-00146-7
Research Highlights
Caliskan Yildirim E, et al. "Treatment Outcomes and Prognostic Factors in N3 Stage Gastric Cancer After ." Cancer management and research, 2023.
N3 gastric cancer is known for its high incidence of lymph node metastasis and unfavorable outcomes despite optimal treatment. To accurately predict the prognosis of patients who underwent curative surgery for N3 gastric cancer, a comprehensive evaluation tool is needed due to the limitations of TNM classification. This study examined the overall survival (OS) of 169 patients who underwent (sub)total gastrectomy and regional lymph node dissection between November 2005 and September 2018. Cox regression analysis revealed significant prognostic factors such as gender, patient performance status, metastatic lymph node ratio (MLNR), tumor grade, and adjuvant chemotherapy. The five-year OS rate was 15%, and most recurrences occurred as distant metastases. Poor prognostic factors included male gender, poor performance status, grade 3 tumors, MLNR> 0.37, and lack of adjuvant chemotherapy. Given the high recurrence rates, further research is necessary to improve treatment approaches for N3 gastric cancer.
Pubmed:
37809035
DOI:
10.2147/CMAR.S412270
He Z, et al. "Development and external validation of a nomogram predicting overall survival for ." Scandinavian journal of gastroenterology, 2023.
The aim of the study was to develop and validate a nomogram for predicting the overall survival (OS) of patients with gastric adenocarcinoma who underwent radical gastrectomy. The training cohort consisted of 3492 patients from 2012 to 2017. Prognostic factors were identified through survival analysis and COX analysis. The nomogram included age, type of surgery, tumor size, T stage, grade, and metastatic lymph node ratio (MLNR). The nomogram outperformed the American Joint Committee on Cancer (AJCC) TNM staging in both the training and external validation cohorts. The nomogram also showed good agreement with actual survival rates and improved predictive ability for 1-year, 3-year, and 5-year OS. The study highlights the potential of using the MLNR-based nomogram to guide clinical treatment decisions and improve survival outcomes for patients with gastric adenocarcinoma.
Pubmed:
37632275
DOI:
10.1080/00365521.2023.2250497
